Weight Loss Injections Dubai Price Guide

Weight Loss Injections Dubai Price — What They Are and Which Are Available

For anyone pricing weight loss injections in Dubai, the current range runs roughly AED 800 to AED 2,800 per month depending on brand, dose, and availability. In this guide, weight loss injections refer to GLP-1 receptor agonists administered by subcutaneous injection. The approved Dubai pharmacy list covers Mounjaro (tirzepatide, weekly), Wegovy (semaglutide 2.4 mg, weekly), Ozempic (semaglutide for type 2 diabetes, weekly), and Saxenda (liraglutide, daily) — each prescription-only and dispensed through licensed UAE pharmacies. These are a medical treatment used to support broader weight loss efforts, and long-term results usually depend on diet, activity, and clinician-guided changes rather than the injection alone.

This comparison is written for UAE-based researchers, clinics, wellness professionals, bulk buyers who need documentation, and international wholesalers weighing products and supply in Dubai. It breaks down which injections are available, how their pricing tiers differ, what clinical-trial efficacy data shows, and how approved pharmacy medicines differ from research-use peptides on procurement, storage, and buyer due diligence.

Retatrutide sits outside that pharmacy list. It remains investigational and is supplied in the UAE as research-use material only — for example by Remy Peptides, a Dubai-based research-use-only peptide supplier — not as an approved weight-loss medicine; where it appears, pricing is typically quoted per pen rather than per monthly pharmacy prescription.

This guide is published by Remy Peptides, a Dubai-based research-use-only peptide supplier; the Dubai pharmacy prices below are directional reference signals, while the retatrutide figures reflect Remy Peptides research-supply references.

Which weight-loss injection has the highest published efficacy?

Weight-loss injectables include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda), and investigational CagriSema. Approved injections are used to help people lose weight, but they work best when they support diet, activity, and clinician-led plans rather than replace them — and how much weight someone loses still varies by molecule, dose, adherence, and starting profile. Results are usually framed as a percentage of body weight. In Phase 3 trials, semaglutide reached about 15% mean weight loss and tirzepatide about 22.5%, while investigational retatrutide reported about 24.2% in Phase 2 (Jastreboff et al., NEJM 2023, DOI 10.1056/NEJMoa2301972). Semaglutide and tirzepatide are MoHAP-approved prescription medicines; retatrutide and CagriSema remain investigational. Because GLP-1-class medicines act on appetite regulation and digestion, they are discussed in relation to overall health as well as weight. Clinical decisions should account for weight loss goals, related risks such as high blood pressure, and whether the plan is built for sustainable weight loss with a licensed prescriber.

How Much Do Weight Loss Injections Cost in Dubai?

If the search is specifically weight loss injections Dubai price, the first thing to understand is that Dubai does not have one clean market price for this category. These medicines target biological factors linked to appetite and digestion, which can help some people lose weight, but Dubai quotes still run from roughly AED 700 up to AED 4,300 per month depending on product, delivery route, and the treatment area being priced. The number changes with dose, brand, stock pressure, consultation fees, and channel, and the right choice often depends on your weight loss goals, overall health, and conditions such as high blood pressure. In practice, most Dubai buyers see four tiers:

• Lower-cost entry tier: Saxenda usually anchors the low end of approved monthly spend.
• Middle semaglutide tier: Ozempic can start lower at smaller pen strengths, but effective monthly spend climbs as refill pace increases.
• Higher-efficacy tier: Mounjaro usually prices above Ozempic but brings a stronger published tirzepatide signal.
• Highest approved semaglutide tier: Wegovy often sits highest on price and lowest on supply consistency.

Published clinical-trial results are usually discussed as a percentage of body weight, which helps answer how much weight studies report during a successful weight loss journey. Some clinic-led packages are advertised much higher — around AED 3,999 to AED 5,999 — while general slimming-injection quotes often average about AED 1,699.

A separate fifth lane is research-use retatrutide. That should not be mixed into the same pharmacy calculation because it is not an approved medicine in Dubai and is normally quoted per pen rather than as a clinic-led monthly refill. Clinical decisions belong with a licensed prescriber, and any treatment plan should support a longer-term weight loss journey rather than rely on medication alone.

Which Weight Loss Injection Is Usually Cheapest in Dubai?

On current Dubai pricing, Saxenda is usually the cheapest approved starting point. That lower price comes with a trade-off: daily injections and a weaker published weight-loss signal than semaglutide 2.4 mg or tirzepatide. For buyers prioritising lowest monthly spend first, Saxenda often wins. For buyers prioritising published efficacy per month spent, the conversation usually shifts to Ozempic or Mounjaro.

Ozempic can look cheaper at the start of a protocol, especially when the comparison is made at lower weekly doses. But once the question becomes, “What is my real monthly spend at the dose I am actually using?” the gap between Ozempic and other weekly options often narrows. That is why an article chasing buyer intent needs to separate starting price from true monthly refill cost.

The number changes with dose, brand, stock pressure, consultation fees, and channel. Clinics may also quote differently depending on the treatment plan set during a patient's weight loss journey.

In practical terms, the lowest entry quote is not always the best value if the aim is long lasting results. It also helps to factor in what happens after treatment, because poor planning can increase the risk of weight regain. Pricing is best judged in the context of a successful weight loss journey, not a single starting quote.

Dubai Price Breakdown: Mounjaro, Ozempic, Wegovy, Saxenda, and Retatrutide

Mounjaro Price Dubai

Mounjaro price Dubai usually lands in the AED 1,500 to AED 2,500 per month range, and the mounjaro injection is typically taken once weekly. Some Dubai clinic listings quote it from around AED 2,800, a clinic-specific benchmark above the lower pharmacy-led range. The spend is higher than Ozempic in most side-by-side checks, but the trade-off is the stronger published tirzepatide signal. In SURMOUNT-1, tirzepatide reached up to 22.4% weight loss, which is why Mounjaro often dominates the “best approved signal” conversation even when it loses the “lowest price” conversation. For Dubai-specific access notes, see our Mounjaro in Dubai guide.

Ozempic Price Dubai

Ozempic price Dubai usually spans a wider range because buyers often compare different pen strengths, refill intervals, and dose targets. A practical range is AED 744 to AED 1,800 per month. Ozempic stays highly visible in Dubai search behaviour because it is familiar, widely discussed, and often easier to find than Wegovy. The key catch is that Ozempic is a semaglutide diabetes brand, so the buyer should separate that reality from the obesity-specific semaglutide conversation. For the local semaglutide angle, see our Ozempic in Dubai guide.

Wegovy Price Dubai

Wegovy price Dubai usually sits above Ozempic, commonly around AED 1,800 to AED 2,800 per month when stock is available. Wegovy was developed specifically for chronic weight management and showed average weight loss of about 14.9% in STEP 1. It is the cleaner obesity-labelled semaglutide story, but the biggest friction in Dubai is often not interest. It is consistent availability. Buyers searching this term are often less worried about whether Wegovy works and more worried about whether they can keep a reliable refill path. For the broader UAE context, see our Wegovy UAE guide.

Saxenda Price Dubai

Saxenda price Dubai usually starts around AED 800 to AED 1,200 per month, which is why it remains important in the lower-budget end of the market. The trade-off is daily injection burden plus lower published weight-loss signal than weekly tirzepatide or semaglutide. Saxenda often wins the affordability conversation, but it rarely wins the “strongest data” conversation.

Retatrutide Dubai Price

Retatrutide Dubai price belongs to a different category entirely. Retatrutide remains investigational, so it is not a Dubai pharmacy medicine. In the local research-supply context, it is normally quoted per pen, not as a monthly prescription refill. On current Remy Peptides references, the 20 mg pen starts around AED 1,200 and the 30 mg pen starts around AED 1,600, with deeper value at research volume. That price needs to be read together with the format: 300 clicks at 0.1 mg per click, Janoshik-backed batch flow, and no reconstitution. For the full proof trail, see Dubai research guide and the COA library.

What Changes Weight Loss Injection Prices and Side Effects in Dubai?

The best-performing buyer pages do not stop at a list of prices. They explain why the prices move. In Dubai, five factors do most of the work:

• Dose intensity: the monthly spend rises as weekly dose rises, especially with semaglutide and tirzepatide protocols.
• Brand versus molecule: semaglutide and tirzepatide pricing depends on whether the search is for the molecule or a brand-specific access path.
• Supply pressure: Wegovy and Mounjaro pricing tends to become less predictable when local stock tightens.
• Clinic and consultation stack: some Dubai routes bundle consult fees or monitoring into the monthly number, and approved prescribing should follow individual assessment by a licensed doctor under DHA rules.
• Channel type: approved pharmacy products and research-use compounds should not be priced as if they belong to the same route.

A separate category is fat dissolving injections, which target and degrade fat cells directly rather than working through the GLP-1 appetite pathway; they are generally discussed for localized stubborn fat rather than the same route as GLP-1-based or other treatments.

That last point matters most for Retatrutide. A research-use pen with COA, fixed click math, and cold-chain handling is not the same purchase flow as an approved pharmacy injection in Dubai. Lumping the two together makes the page less useful and less trustworthy. For safe, regulated access, a proper assessment and medical assessment come before starting treatment.

Which Injection Has the Strongest Published Weight-Loss Data?

For buyers who care about value per published signal, the hierarchy stays consistent. Tirzepatide leads the approved field, semaglutide 2.4 mg sits behind it, and liraglutide sits further back. Broadly, this is how these injections work: they can reduce appetite and slow digestion to promote weight loss, which helps explain why stronger data often tracks with stronger biological effect. In published trial data:

• Tirzepatide: up to 22.4% in SURMOUNT-1
• Semaglutide 2.4 mg: about 14.9% in STEP 1
• Liraglutide 3.0 mg: about 8% in SCALE
• Retatrutide: 24.2% in Phase 2, but still investigational

That means the core Dubai decision is usually not, “Which one works at all?” It is, “Do I want the lowest spend, the strongest approved data, the easiest refill path, or the strongest research-only signal?” If the question is specifically about approved products, Mounjaro carries the strongest argument. If the question is specifically about research, Retatrutide leads the current published signal and connects naturally to our Retatrutide vs Tirzepatide vs CagriSema analysis.

Mounjaro Market Scale — Q1 2026 Demand Context

The data hierarchy above maps to real-world market uptake. Eli Lilly's Q1 2026 earnings (April 30, 2026) reported Mounjaro worldwide at $8.66B (+125% YoY), with ex-US sales of US$4.4B (up from US$1.2B a year earlier) — making tirzepatide the world's highest-revenue obesity-related pharmacotherapy. Zepbound (tirzepatide, US obesity brand) posted US$4.2B (+80% YoY) in the US alone. That supply pressure is a direct driver of the availability and pricing volatility Dubai buyers see in the Mounjaro channel.

For Wegovy / semaglutide context: a prespecified substudy of the SELECT cardiovascular trial (Nature Medicine, April 2026) found that among participants with elevated liver fibrosis markers (FIB-4 ≥1.3), semaglutide reduced the fatty liver index ~28% more than placebo (HR 0.72; p<0.0001) over 104 weeks — adding a hepatic benefit dimension to the semaglutide data set that buyers with MASLD risk may find relevant. A separate meta-analysis of 4 RCTs (Sleep & Breathing, April 24, 2026) found GLP-1 RAs reduced apnoea-hypopnoea index (AHI) by a mean of 13.89 events/hour (95% CI −22.86 to −4.92, p<0.01) alongside 4–6 mmHg systolic BP reductions — a clinically relevant dual signal for buyers with obesity-related sleep apnoea or cardiovascular risk. For the registered 2026 trial-emulation record comparing tirzepatide and semaglutide on cardiovascular outcomes, see our tirzepatide vs semaglutide CV outcomes brief.

Dubai Buyer Checklist Before Paying

Pages built for buyer intent work better when they end with a practical checklist. Before paying, check:

• Is this a pharmacy product or a research product? The answer changes the whole compliance and delivery framework.
• Is the quoted number monthly or per pen? That difference is where many weak comparison pages fail.
• Does the route depend on a prescription? Approved Dubai pharmacy products do.
• Is candidacy based on eligibility review? Many approved protocols start around a body mass index (BMI) of 30 or above, but individual assessment still matters, and your weight loss goals should be clear before you pay for an assessment.
• Is pregnancy an exclusion? Pregnant women are generally not considered eligible for treatment.
• Are side effects explained clearly? The most reported issues are digestive — including nausea and stomach upset — especially in the first few weeks.
• Is there a plan to manage tolerability? Side effects usually ease as the body adjusts, and gradual dose increases under medical supervision are commonly used to reduce them.
• Does the clinic give guidance on diet? A healthy diet and a balanced diet matter for more sustainable results.
• Is urgent-risk guidance stated? Serious side effects are less common, but they require prompt medical attention.
• Is stock stable or intermittent? Wegovy and some Mounjaro routes can be more supply-sensitive.
• What proof accompanies the product? In the research category, COA and batch verification matter more than marketing copy.
• Will the provider help you maintain results after treatment? Ask how they reduce the chance of weight regain — long-term planning beats a single starting quote.
• Does the page actually show the next step? For Mounjaro, Ozempic, Wegovy, and UAE GLP-1 context, follow the product-specific pages. For research-use retatrutide, follow the proof stack: Dubai page, pen guide, clicks guide, and calculator.